The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis

European Cytokine Network

Volumn 9, Issue 2, 1998, Pages 145-154

  Robak, Tadeusz ^a   Gla̧dalska, Anna ^b   Stȩpień, Henryk ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b City Hospital   (Poland)

Author keywords

Disease activity; Lymphotoxin ; Rheumatoid arthritis; TNF soluble receptors; TNF ; TNF

Indexed keywords

LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; SERUM;

ADULT; AGED; ANTIGENS, CD; ARTHRITIS, RHEUMATOID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIGANDS; LINEAR MODELS; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

MYRISTICA FRAGRANS;

EID: 0031811543     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Weyand C M, Goronzy J J. 1997. Pathogenesis of rheumatoid arthritis. Med. Clin. North Am. 81: 29.
2. Strober S, Holoshitz, J. 1990. Mechanism of immune injury in rheumatoid arthritis: evidence for the involvement of T cells and heat-shock proteins. (Review) Immunol. Rev. 118: 233.
3. Firenstein G S, Zvaifler N J. 1990. How important are T cells in chronic rheumatoid synovits? Arthritis Rheum. 33: 768.
4. Koch A E, Kunkel S L, Strieter R M. 1995. Cytokines in rheumatoid arthritis. J. Investig. Med. 43: 28.
5. Brennan F M, Maini R N, Feldmann M. 1995. Cytokine expression in chronic inflammatory disease. (Review) Br. Med. Bull. 51: 368.
6. Arend W P, Dayer J M. 1995. Inhibition of the production and efects of interleukin-1 and TNF-α in rheumatoid arthritis. Arthritis Rheum. 58: 151.
7. Holt I, Cooper R G, Denton J, Meager A, Hopkins S J. 1992. Cytokine inter-relationships and their association with disease activity in arthritis. Br. J. Rheumatol. 31: 725.
8. MacNaul K L, Hutchinson N I, Parsons J N, Bayne E K, Tocci M J. 1990. Analysis of IL-1 and TNF-α gene expression in rheumatoid synoviocytes and normal monocytes by in situ hybridization. J. Immunol. 145: 4154.
9. Chu C Q, Field M, Feldmann M, Maini R N. 1991. Localization of tumor necrosis factor-α in synovial tissues and at the cartilage pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34: 1125.
10. Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C. 1990. Tumor necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann. Rheum. Dis. 49: 665.
11. Manicourt D H, Triki R, Fukuda K, Devogelaer J P, Nagant de Deuxchaisnes C, Thonar E J. 1993. Levels of circulating tumor necrosis factor-α and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum. 36: 490.
12. Beutler B, van Huffel C. 1994. Unraveling function in the TNF ligand and receptor families. Science 264: 667.
13. Bazzoni F, Beutler B. 1996. The tumor necrosis factor ligand and receptor families. (Review) N. Engl. J. Med. 334: 1717.
14. Hohmann H P, Remy R, Brockhaus M, van Loon A P. 1989. Two different cell types have different major receptors for human tumor necrosis factor (TNF-α). J. Biol. Chem. 264: 14927.
15. Brockhaus M, Schonfeld H J, Schlaeger E J, Hunziker W, Lesslauer W, Loetscher H. 1990. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 87: 3127.
16. Diez-Ruiz A, Tilz G P, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. 1995. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. (Review) Eur. J. Haematol. 54: 1.
17. Aderka D, Engelmann H, Hornik V, Skornick Y, Levo Y, Wallach D, Kusatai G. 1991. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 51: 5602.
18. Heilig B, Wermann M, Gallati H, Brockhaus M, Berke B, Egen O, Pezzutto A, Hunstein W. 1992. Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis. Clin. Investig. 70: 22.
19. Cope A P, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones A C, Brennan F M, Maini R N, Wallach D, Feldmann M. 1992. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 35: 1160.
20. Steiner G, Studnicka-Benke A, Witzmann G, Hofler E, Smolen J. 1995. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J. Rheumatol. 22: 406.
21. Heilig B, Wermann M, Gallati H, Brockhaus M, Berke B, Egen O, Pezzuto A, Hunstein W. 1992. Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis. Clin. Investig. 70: 22.
22. Roux-Lombard P, Punzi L, Hasler F, Bas S, Todesco S, Gallati H, Guerne P A, Dayer J M. 1993. Soluble tumor necrosis factor receptors in human inflamatory synovial fluids. Arthritis Rheum. 36: 485.
23. Heilig B, Fiehn C, Brockhaus M, Gallati M, Pezzutto A, Hunstein W. 1993. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease. J. Clin. Immunol. 12: 321.
24. Tilz G P, Diez-Ruiz A, Baier-Bitterlich G, Demel U, Wachter H, Fuhs D. 1996. Soluble receptors for tumor necrosis factor and neoptein as parameters of cell-mediated immune activation. Haematology 1: 141.
25. Arnett F C, Edworthy S M, Bloch D A, McShane D J, Fries J E, Cooper N S, Healey L A, Kaplan S R, Liang M H, Luthra H S, Measger T A J, Mitchell D M, Neustadt D H, Pinals R S, Schaller J G, Sharp J T, Wider R L, Hunder G G. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315.
26. Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA. 1958. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull. Rheum. Dis. 9: 175.
27. Hochberg M C, Chang R W, Dwosh I, Lindsey S, Pincus T, Wolfe F. 1992. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 35: 498.
28. Ritchie D M, Boyle J A, McInnes J M, Jasani M K, Dalakos T G, Grieveson P, Buchaman W W. 1968. Clinical studies with an articular index for the assessments of joint tenderness in patients with rheumatoid arthritis. Q.J. Med. 147: 393.
29. Mallya R K, Mace B E W. 1981. The assessment of disease activity in rheumatoid arthritis using a multivariate analysis. Rheumatol. Rehabil. 20: 14.
30. Robak E, Sysa-Jȩdrzejowska A, Robak T, Stȩpień H, Wozniacka A, Waszczykowska E. 1996. Tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6) and their soluble receptors (sTNF-α-R p55 and sIL-6R) serum levels in systemic lupus erythematodes. Mediators Inflamm. 5: 435.
31. Robak E, Sysa-Jȩdrzejowska A, Stȩpień H, Robak T. 1997. Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus. Eur. Cytokine Nerv. 8: 281.
32. Brennan F M, Maini R N, Feldmann H. 1995. Cytokine expression in chronic inflamatory disease. (Review) Br. Med. Bull. 51: 368.
33. Ivashkiv L B. 1996. Cytokine expression and cell activation in inflammatory arthritis. (Review) Adv. Immunol. 63: 337.
34. Saxne T, Palladino M A Jr, Heinegard D, Talal N, Wollheim F A. 1988. Detection of tumor necrosis factor-α but not tumor necrosis factor-β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 31: 1041.
35. Brennan F M, Chantry D, Jackson A, Maini R N, Feldmann M. 1989. Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2: 244.
36. Warzocha K, Salles G, Bienvenu J, Bastion Y, Dumontet C, Renard N, Neidhardt-Berard E M, Coiffier B. 1997. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J. Clin. Oncol. 15: 499.
37. Steiner G, Studnicka-Benke A, Witzmann G, Hofler E, Smoleń J. 1995. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J. Rheumatol. 22: 406.
38. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D C. 1995. Soluble receptors for tumor necrosis factor in clinical laboratory diagnosis. (Review) Eur. J. Haematol. 54: 1.
39. Bigda J, Holtmann H. 1997. TNF receptors-how they function and interact. Arch. Immunol. Ther. Exp. 45: 263.
40. Trefzer U, Brockhaus M, Loetscher H, Parlow F, Budnik A, Grewe M, Christoph H, Kapp A, Schopf E, Langer TA, Krutmann J. 1993. The 55-kD tumor necrosis factor receptor on human keratinocytes is regulated by tumor necrosis factor-alpha and by ultraviolet B radiation. J. Clin. Invest. 92: 462.
41. Kalthoff H, Roeder C, Brockhaus M, Thiele H G, Schmiegel W. 1993. Tumor necrosis factor upregulates the expression of p75 but not p55 TNF receptors and both receptors mediate, independently of each other, up-regulation of transforming growth factor-α and epidermal growth factor receptor mRNA. J. Biol. Chem. 268: 2762.
42. Engelberts J, Moller A, Schoen G J, van der Linde C J, Buurman W A. 1991. Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res. 10: 69.
43. Barrera P, Boerbooms A M, Demacker P N, van de Putte L B, Gallati H, van der Meer J W. 1994. Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dose of methotrexate. Br. J. Rheumatol. 33: 1017.
44. Barrera P, Haagsma C J, Boerbooms A M, Van Riel P L, Borm GE, Van de Putte L B, Van der Meer J W. 1995. Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Br. J. Rheumatol. 34: 747.
45. Heaney M L, Golde D W. 1996. Soluble cytokine receptors. (Review) Blood 87: 847.
46. Van Zee K J, Kohno T, Fischer E, Rock C S, Moldawer L L, Lowry S F. 1992. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflamation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc. Natl. Acad. Sci. USA 89: 4845.
47. Aderka D, Engellmann H, Maor Y, Brakebusch C, Wallach D. 1992. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 175: 323.
48. Danis V A, Franic G M, Rathjen A, Laurent R M, Brooks P M. 1992. Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulfasalazine. Ann. Rheum. Dis. 51: 946.
49. Elliott M J, Feldmann M, Maini R N. 1995. TNF-α blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanism of action. (Review) Int. J. Immunopharmacol. 17: 141.
50. Firestein G S, Zvaifler N J. 1997. Anticytokine therapy in rheumatoid arthritis. N. Engl. J. Med. 337: 195.
51. Williams R O, Mason L J, Feldmann M, Maini R N. 1994. Synergy between anti-CD 4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 91: 2762.
52. Maini R N, Elliott M J, Brennan F M, Williams R O, Chu C Q, Paleolog E, Charles P J, Taylor P C, Feldmann M. 1995. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. (Review) Immunol. Rev. 144: 195.
53. Moreland L W, Baumgartner S W, Schiff M H, Tindall E A, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer M B, Blosch C M. 1997. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337: 141.